Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mineral oils, specifically formulated as cationic oil-in-water emulsions such as Cationorm, are used as topical ophthalmic lubricants for the symptomatic treatment of dry eye disease (DED). These formulations function by replenishing and stabilizing the lipid layer of the tear film, which significantly reduces tear evaporation and protects the ocular surface from desiccation and irritation. Unlike immunomodulatory agents that target specific inflammatory pathways, mineral oils act through a physical mechanism to provide long-lasting relief from symptoms like burning, itching, and foreign body sensation. In clinical research, such as the University of New South Wales trial (NCT06898853), mineral oil-based drops are frequently utilized as active comparators or supportive therapies to evaluate the efficacy of anti-inflammatory treatments like cyclosporine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mineral oils.